{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:56:57Z","timestamp":1792155417852,"version":"4.4.0"},"reference-count":30,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030734","name":"J-Pharma Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100030734","id-type":"DOI","asserted-by":"crossref"}]},{"id":[{"id":"https:\/\/ror.org\/05b2z2644","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background\/Objectives: This exploratory post hoc analysis evaluated clinical and biomarker-defined treatment effects and accumulated nanvuranlat exposure in advanced biliary tract cancer (BTC). Methods: BICR-assessed progression-free survival (PFS) and overall survival (OS) were analyzed in the randomized Phase 2 full analysis set of 104 patients (nanvuranlat, n = 69; placebo, n = 35). Formal treatment-by-subgroup interaction tests assessed prior primary tumor resection status, LAT1 expression, and anatomical BTC subtype, evaluated both as a four-category variable and as pooled IHC\/EHC\/GBC versus AVC. Accumulated-exposure analyses pooled Phase 1 and Phase 2 data and were descriptive. Results: Median PFS was 46 versus 43 days (HR, 0.557; 95% CI, 0.344\u20130.903), and median OS was 155 versus 144 days (HR, 0.875; 95% CI, 0.551\u20131.390). Interaction tests were nominally significant for resection status with OS (p = 0.028) and for the four-category BTC-subtype variable with PFS (global p = 0.035), but not for LAT1 expression (PFS, p = 0.157; OS, p = 0.586) or pooled IHC\/EHC\/GBC versus AVC (PFS, p = 0.511; OS, p = 0.208). The binary and four-category subtype analyses addressed different hypotheses and were not considered contradictory. Higher accumulated-exposure quartiles showed numerically longer survival, but these analyses were susceptible to immortal-time bias, reverse causation, and time-dependent confounding. Conclusions: Nanvuranlat was associated with a lower hazard of progression or death than placebo, whereas the OS estimate was less conclusive. The subgroup and exposure findings remain exploratory but support prospective evaluation of resection status, anatomical subtype, and LAT1 expression.<\/jats:p>","DOI":"10.3390\/cancers18152492","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T08:02:19Z","timestamp":1785830539000},"page":"2492","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical and LAT1 Biomarker Correlates of Clinical Benefit from Nanvuranlat (JPH203) in Advanced Biliary Tract Cancer: A Post Hoc Analysis"],"prefix":"10.3390","volume":"18","author":[{"given":"Eric K.","family":"Rowinsky","sequence":"first","affiliation":[{"name":"Uniphar Development, LLC, Rockville, MD 20850, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghassan K.","family":"Abou-Alfa","sequence":"additional","affiliation":[{"name":"Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA"},{"name":"Weill Cornell College, Cornell University, New York, NY 10065, USA"},{"name":"School of Medicine, Trinity College Dublin, D02 PN40 Dublin, Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0663-6117","authenticated-orcid":false,"given":"Junji","family":"Furuse","sequence":"additional","affiliation":[{"name":"Kanagawa Cancer Center, Yokohama 241-8515, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4480-0029","authenticated-orcid":false,"given":"Makoto","family":"Ueno","sequence":"additional","affiliation":[{"name":"Kanagawa Cancer Center, Yokohama 241-8515, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4050-2086","authenticated-orcid":false,"given":"Masafumi","family":"Ikeda","sequence":"additional","affiliation":[{"name":"National Cancer Center Hospital East, Kashiwa 277-8577, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0322-200X","authenticated-orcid":false,"given":"Hiroko","family":"Tabuchi","sequence":"additional","affiliation":[{"name":"ssg medical Inc., Kumamoto 860-0803, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8086-5983","authenticated-orcid":false,"given":"Kazuo","family":"Sekiguchi","sequence":"additional","affiliation":[{"name":"J-Pharma Co., Ltd., Tokyo 105-0013, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Szarek","sequence":"additional","affiliation":[{"name":"Division of Cardiology, University of Colorado Anschutz School of Medicine, Aurora, CO 80045, USA"},{"name":"CPC Clinical Research, Aurora, CO 80045, USA"},{"name":"School of Public Health, State University of New York, Downstate Health Sciences University, Brooklyn, NY 11203, USA"},{"name":"Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: The next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"Nakamura","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): A randomized, double-blind, placebo-controlled, Phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1002\/cam4.5282","article-title":"Real-world outcomes among patients with advanced or metastatic biliary tract cancers initiating second-line treatment","volume":"12","author":"Cosgrove","year":"2023","journal-title":"Cancer Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): A Phase 3, open-label, randomized, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1001\/jamaoncol.2023.0016","article-title":"Treatment with liposomal irinotecan plus fluorouracil and leucovorin for patients with previously treated metastatic biliary tract cancer: The Phase 2b NIFTY randomized clinical trial","volume":"9","author":"Hyung","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"H\u00e4fliger, P., and Charles, R.-P. (2019). The L-type amino acid transporter LAT1\u2014An emerging target in cancer. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20102428"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Kaira, K., Sunose, Y., Ohshima, Y., Ishioka, N.S., Arakawa, K., Ogawa, T., Sunaga, N., Shimizu, K., Tominaga, H., and Oriuchi, N. (2013). Clinical significance of L-type amino acid transporter 1 expression as a prognostic marker and potential of new targeting therapy in biliary tract cancer. BMC Cancer, 13.","DOI":"10.1186\/1471-2407-13-482"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/cam4.272","article-title":"High expression of L-type amino acid transporter 1 as a prognosis marker in bile duct adenocarcinomas","volume":"3","author":"Yanagisawa","year":"2014","journal-title":"Cancer Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"105670","DOI":"10.1016\/j.humpath.2024.105670","article-title":"Expression of the large amino acid transporter SLC7A5\/LAT1 on immune cells is enhanced in primary sclerosing cholangitis-associated cholangiocarcinoma and correlates with poor prognosis in cholangiocarcinoma","volume":"153","author":"Branchi","year":"2024","journal-title":"Hum. Pathol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1186\/s13046-023-02845-4","article-title":"Amino acid metabolism reprogramming: Shedding new light on T cell anti-tumor immunity","volume":"42","author":"Zheng","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13045-023-01453-1","article-title":"Amino acid metabolism in immune cells: Essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy","volume":"16","author":"Yang","year":"2023","journal-title":"J. Hematol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00726-025-03456-3","article-title":"LAT1 inhibition remodels the tumor immune microenvironment and enhances anti-PD-1 therapy in triple-negative breast cancer","volume":"57","author":"Zhao","year":"2025","journal-title":"Amino Acids"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Huang, R., Wang, H., Hong, J., Wu, J., Huang, O., He, J., Chen, W., Li, Y., Chen, X., and Shen, K. (2023). Targeting glutamine metabolic reprogramming of SLC7A5 enhances the efficacy of anti-PD-1 in triple-negative breast cancer. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1251643"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1111\/jcmm.17553","article-title":"Pharmacologic inhibition of LAT1 predominantly suppresses transport of large neutral amino acids and downregulates global translation in cancer cells","volume":"26","author":"Nishikubo","year":"2022","journal-title":"J. Cell. Mol. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1038\/s41598-025-87522-6","article-title":"Pharmacological and structural insights into nanvuranlat, a selective LAT1 (SLC7A5) inhibitor, and its N-acetyl metabolite with implications for cancer therapy","volume":"15","author":"Jin","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1038\/s41467-025-56903-w","article-title":"Structural basis of anticancer drug recognition and amino acid transport by LAT1","volume":"16","author":"Lee","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1010428317694545","DOI":"10.1177\/1010428317694545","article-title":"Inhibition of L-type amino acid transporter 1 activity as a new therapeutic target for cholangiocarcinoma treatment","volume":"39","author":"Yothaisong","year":"2017","journal-title":"Tumour Biol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Otani, R., Takigawa, H., Yuge, R., Shimizu, D., Ariyoshi, M., Miyamoto, R., Kadota, H., Hiyama, Y., Hayashi, R., and Urabe, Y. (2023). The anti-tumor effect of the newly developed LAT1 inhibitor JPH203 in colorectal carcinoma, according to a comprehensive analysis. Cancers, 15.","DOI":"10.3390\/cancers15051383"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1007\/s10637-020-00924-3","article-title":"First-in-human Phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors","volume":"38","author":"Okano","year":"2020","journal-title":"Investig. New Drugs"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1158\/1078-0432.CCR-24-0461","article-title":"A Phase II placebo-controlled study of the effect and safety of nanvuranlat in patients with advanced biliary tract cancers previously treated by systemic chemotherapy","volume":"30","author":"Furuse","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_24","first-page":"3968","article-title":"Biomarker: Predictive or prognostic? J","volume":"33","author":"Ballman","year":"2015","journal-title":"Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"S232","DOI":"10.1016\/j.annonc.2025.08.531","article-title":"98P Subgroup analysis of a Phase II study of nanvuranlat in pre-treated, advanced, refractory biliary tract cancer patients support an enriched patient population for a planned Phase III study","volume":"36","author":"Ueno","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/s41575-022-00741-4","article-title":"Immunology and immunotherapy of cholangiocarcinoma","volume":"20","author":"Greten","year":"2023","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.jhep.2022.04.038","article-title":"Metabolic reprogramming in cholangiocarcinoma","volume":"77","author":"Raggi","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10928-023-09850-2","article-title":"A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development","volume":"50","author":"Baverel","year":"2023","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_29","unstructured":"U.S. Food and Drug Administration (2003). Exposure\u2013Response Relationships: Study Design, Data Analysis, and Regulatory Applications, U.S. Food and Drug Administration. Guidance for Industry."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Lin, Y.-W., Largajolli, A., Edwards, A.Y., Cheung, S.Y.A., Patel, K., and Hennig, S. (2025). Impact of using time-averaged exposure metrics on binary endpoints in exposure-response analyses. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1487062"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2492\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T04:12:41Z","timestamp":1785989561000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/15\/2492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":30,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18152492"],"URL":"https:\/\/doi.org\/10.3390\/cancers18152492","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]}}}